Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (296)	12/17/1998 6:28:00 PM
From: mike head	Respond to of 1073

Nigel. There is a rather positive press release yesterday, on the Chiroscience web site chiroscience.com the Fda has issued a letter of intent to review chirocaine early in January. Chirocaine also received Swedish approval. All of this FWIW. Pax et bonum,mch

To: nigel bates who wrote (296)	12/17/1998 7:45:00 PM
From: scaram(o)uche	Respond to of 1073

Nigel: There was an article about it in this week's BioCentury. I was surprised to see how badly they got clocked. Nope, I don't know stuff like this at all. Jim Silverman knows the company, so maybe he has a clue. I guess any company that is involved in the sale of lidocaine? Not with any real knowledge, but it seems like Ethicon (JNJ) might have an interest? I was very impressed by the first-blush glance that I took at their MPI program, and BBIOF discontinued a clinical trial yesterday (today?). So, that might be another negative..... British Biotech having yet another negative impact of british biotechs. ;-) Rick